2013-05-23T01:43:18Z http://repub.eur.nl/oai

oai:repub.eur.nl/res/pub/28217 2012-12-06T11:14:30Z org:9805 org:9755 org:9833 org:9746 access:open type:article

urn:NBN:nl:ui:15-1765/28217 2012-12-06T11:14:30 mods http://hdl.handle.net/1765/28217 hdl:1765/28217 urn:NBN:nl:ui:15-1765/28217 doi:10.1183/09031936.00139508 Respiratory medicines for children: Current evidence, unlicensed use and research priorities text article http://hdl.handle.net/1765/28217 http://dx.doi.org/10.1183/09031936.00139508 text/html born digital This European Respiratory Society task force has reviewed the evidence for paediatric medicines in respiratory disease occurring in adults and children. We describe off-licence use, research priorities and ongoing studies. Off-licence and off-label prescribing in children is widespread and potentially harmful. Research areas in asthma include novel formulations and regimens, and individualised prescribing. In cystic fibrosis, future studies will focus on screened infants and robust outcome measures are needed. Other areas include new enzyme and antibiotic formulations and the basic defect. Research into pneumonia should include evaluation of new antibacterials and regimens, rapid diagnostic tests and, in pleural infection, antibiotic penetration, fibrinolytics and surveillance. In uncommon conditions, such as primary ciliary dyskinesia, congenital pulmonary abnormalities or neuromuscular disorders, drugs indicated for other conditions (e.g. dornase alfa) are commonly used and trials are needed. In neuromuscular disorders, the β-agonists may enhance muscle strength and are in need of evaluation. Studies of antibiotic prophylaxis, immunoglobulin and antifungal drugs are needed in immune deficiency. We hope that this summary of the evidence for respiratory medicines in children, highlighting gaps and research priorities, will be useful for the pharmaceutical industry, the paediatric committee of the European Medicines Agency, academic investigators and the lay public. Copyright Smyth, A.R. Smyth A.R. aut Barbato, A. Barbato A. aut Beydon, N. Beydon Nicole aut Bisgaard, H. Bisgaard H. aut Boeck, K. de Boeck, de K. aut Brand, P.L.P. Brand Paul L.P. aut Bush, A. Bush A. aut Fauroux, B. Fauroux Brigitte aut Jongste, J.C. de Jongste, de Johan aut Korppi, M. Korppi M. aut O'Callaghan, C. O'Callaghan C. aut Pijnenburg, M.W.H. Pijnenburg Mariëlle aut Ratjen, F. Ratjen Felix aut Southern, K. Southern K. aut Spencer, D. Spencer D. aut Thomson, A. Thomson A. aut Vyas, H. Vyas H. aut Warris, A. Warris Adilia aut Merkus, P.J.F.M. Merkus Peter aut 073184586 294723501 104076135 Erasmus MC: University Medical Center Rotterdam Supporting host sht en English The European Respiratory Journal 0903-1936 35 2 247 265 2010-02-01 Pharmacotherapy Evidence-based medicine Clinical trails Paediatric respiratory diseases Erasmus University Rotterdam oai:repub.eur.nl/res/pub/28217 IR OAIPMH feed (http://repub.eur.nl/oai) 2011-11-22T14:02:59Z 2011-11-30T14:30:50Z http://purl.org/eprint/accessRights/OpenAccess